Evidence map›Paper›PMID 40560497›Full record

ReviewAnnals of surgical oncology2026

Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases.

Kurt S Schultz, Varun V Bansal, Michael M Wach, Neal Bhutiani, Frederick A Godley, Jaeyun Jane Wang, Muhammad Talha Waheed, Joanna T Buchheit, Emily Papai, Susan Campbell and 15 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Kurt S SchultzDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
Varun V BansalDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
Michael M WachDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Neal BhutianiDepartment of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Frederick A GodleyDepartment of Surgery, University of Chicago Medical Center, Chicago, IL, USA.
Jaeyun Jane WangDepartment of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Muhammad Talha WaheedDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Joanna T BuchheitDepartment of Surgery, Penn State College of Medicine, Hershey, PA, USA.
Emily PapaiDepartment of Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Susan CampbellDepartment of Surgery, University of Vermont, Burlington, VT, USA.
Lauren E SchleimerDepartment of Surgery, Columbia University Irving Medical Center, New York, NY, USA.
David G SuDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA.
Kiran K TuragaDepartment of Surgery, Yale School of Medicine, New Haven, CT, USA. kiran.turaga@yale.edu.
Craig G GundersonDepartment of Medicine, Yale School of Medicine, New Haven, CT, USA.
Michael G WhiteDepartment of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abhineet UppalDepartment of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kanwal P S RaghavDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX, USA.
Daniel M LabowDepartment of Surgery, Danbury Hospital, Nuvance Health, Danbury, CT, USA.
Umut SarpelDepartment of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Ardaman P ShergillDepartment of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.
John Paul ShenDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston TX, USA.
Cathy EngDepartment of Medicine, Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Michael B FooteDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Joel M BaumgartnerDivision of Surgical Oncology, Department of Surgery, University of California San Diego, San Diego, CA, USA.
Peritoneal Surface Malignancies (PSM) Consortium Group

Funding

Yale Cancer Center Advanced Training Program for Physician-Scientists (YCC-ATPP)T32CA233414 · NCI · YALE UNIVERSITY · PI Eric P. Winer · 2019 to 2026
$3.2M
Cancer Prevention and Research Institute of Texas RP240392Cancer Prevention and Research Institute of Texas RR180035NCI NIH HHS T32 CA233414
6 · The paper itself

Abstract

backgroundThe peritoneum is a common site of metastases from colorectal cancer (CRC), yet controversy exists regarding optimal treatment strategies. These guidelines describe the results of a national consensus addressing the management of CRC with peritoneal metastases (CRC-PM).

methodsAn update of the 2018 Chicago Consensus Guidelines was conducted using a modified Delphi technique. Two rounds of voting were performed to assess agreement levels on two clinical management pathways regarding synchronous and metachronous CRC-PM. Supporting evidence was evaluated via rapid literature reviews.

resultsThe overall level of evidence was low in existing literature. Of 145 participants in the first round, 136 (96.8%) responded in the second round. Over 90% consensus was achieved in most pathway blocks. For both pathways, early referral to a peritoneal surface malignancy (PSM) center should be made for patients with CRC-PM. For the synchronous pathway, upfront cytoreductive surgery was de-emphasized in favor of systemic therapy. For the metachronous pathway, risk stratification via clinical and pathologic features was revised. For both pathways, surveillance strategies were added, including only a weak recommendation for circulating tumor DNA (ctDNA) testing given limited evidence of its utility in detecting and monitoring PM.

conclusionThe consensus-driven clinical pathways provide valuable guidance for the management of CRC-PM. There remains a need for high-quality evidence and prospective multicenter trials in this domain.

Indexed as

Colorectal NeoplasmsPeritoneal NeoplasmsPractice Guidelines as TopicConsensusCytoreduction Surgical ProceduresDelphi TechniqueHumansPrognosisColon cancerColorectal cancerctDNACytoreductive surgeryGuidelinesIntraperitoneal chemotherapyPeritoneal surface malignanciesPeritoneal surface neoplasmsRectal cancer

Identifiers

PMID40560497

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.